麻豆视频

Middle East And Africa Diabetes Drugs Market Trends and Insights

Rising Prevalence of Diabetes & Obesity

Newly published 2024 hospital registry updates confirm double-digit diabetes prevalence across GCC states, with Saudi clinics reporting baseline HbA1c readings above 10% in incoming patients, underscoring the severity of metabolic deterioration.^{[1]Elsevier, “Oral Semaglutide Effectiveness in Real-World Practice,” deman.elsevier.com} Urban migration, dietary westernization, and sedentary work patterns continue to raise body-mass indices, lengthening lifetime treatment duration. The trend is spreading southward as processed foods penetrate major African cities where healthcare access is fragmented. For pharmaceutical companies, this enlarges the addressable population for basal insulin, GLP-1 agonists, and emerging once-weekly pills. It also strengthens the case for preventive public-health spending, which in turn supports formularies covering weight-control agents.

Government Initiatives for Improving Diabetic Medication Access

Saudi Arabia’s National Unified Procurement Company (NUPCO) signed ten memoranda of understanding with multinational manufacturers in October 2024 to localize insulin and GLP-1 production, improving supply security while meeting Vision 2030 objectives. Egypt followed suit in December 2024 when Eli Lilly and EVA Pharma launched the first domestically produced insulin glargine, targeting one million patients by 2030. In the UAE, the 2025 Federal Decree-Law No. 38 sets conditional approval pathways and mandatory pharmacovigilance, shortening the time to market for innovative molecules.^{[2]UAE Government, “Federal Decree-Law Governing Medical Products, Pharmacists and Pharmaceutical Establishments,” uaelegislation.gov.ae}Collectively, these policies reduce import dependence, enforce quality standards, and foster technology transfer, making locally sourced biologics more affordable.

Expanding Health Insurance Coverage in GCC

Comprehensive insurance mandates are reshaping buying power. A 2024 real-world tirzepatide study in an Arab cohort showed that 64.1% of insured patients achieved HbA1c targets below 7% within 40 weeks despite the drug’s premium price point.^{[3]Elsevier, “Oral Semaglutide Effectiveness in Real-World Practice,” deman.elsevier.com}As Gulf payers broaden diabetes formularies, innovative therapies experience faster uptake, allowing manufacturers to maintain value-based pricing while reducing out-of-pocket expenditures for nationals and expatriates alike. Wider coverage also drives adherence because patients can afford continuous glucose-monitoring (CGM) sensors and follow-up consultations. For multinational firms, it signals a shift away from volume-driven tender models toward outcomes-driven contracting.

Rapid Growth of e-Pharmacy Platforms

Saudi Arabia’s clarification of online dispensing rules in 2024 enabled fully licensed e-pharmacies to cover the complete reimbursement spectrum, propelling penetration from single digits pre-COVID to more than half of repeat prescriptions today. Similar reforms are being drafted in Qatar and Bahrain, unlocking regional scale for digital platforms. Patients appreciate home delivery, discreet counseling, and automated refill reminders, attributes that are particularly valuable for chronic diseases. Health-tech start-ups now integrate e-pharmacies with remote endocrinology consults, creating data ecosystems that support personalized titration algorithms. For wholesalers, online channels reduce last-mile costs and improve demand-forecast accuracy.

High Cost of Novel Therapies

Even as the Middle East and Africa diabetes drugs market expands, affordability gaps widen between affluent GCC consumers and low-income groups in Sub-Saharan Africa. A 2025 qualitative assessment across Ethiopian primary-care clinics found that constrained household budgets, scarce insurance options, and limited device availability continue to hamper optimal care, especially for insulin-requiring patients. Nigerian field interviews completed in June 2024 revealed that more than 80% of respondents considered branded medication prices prohibitive, steering them toward older generics. Consequently, manufacturers must craft tiered-pricing and donation programs while governments seek bulk-procurement partnerships to bridge therapeutic inequality.

Counterfeit Drugs in Informal Channels

Conflict-affected zones remain fertile ground for substandard antidiabetic products. A May 2025 study examining supply routes into Yemen documented that up to 60% of sampled medicines failed regulatory specifications, putting patients at risk of treatment failure and complications. Smugglers exploit porous borders and shortages of fully licensed pharmacies, undermining trust in legitimate brands. Health authorities are responding with barcode-based track-and-trace systems and mobile-app verification. For multinational companies, stronger serialisation requirements raise compliance costs but protect market share by assuring product integrity.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Therapy Class: Injectables Erode Oral Dominance

Non-insulin injectables are projected to grow at 8.98% annually, gradually eating into the 38.05% share that oral drugs held in 2025. The shift became evident when Saudi clinicians documented a 3.1% mean HbA1c decline and a 19.7% BMI reduction six months after initiating oral semaglutide in routine practice. The Middle East and Africa diabetes drugs market size for non-insulin injectables is expected to climb at double the pace of basal insulin because payers are linking reimbursement to weight management and cardiovascular outcomes. Weekly tirzepatide therapy replicated pivotal-trial efficacy in a 2024 UAE cohort, with nearly two-thirds of patients achieving glycemic targets inside 40 weeks. These results embolden regional formularies to list premium GLP-1/GIP co-agonists earlier in treatment algorithms.

GLP-1 demand is also spreading south as Novo Nordisk and Aspen begin local insulin cartridge production in South Africa, freeing capacity to import incretin mimetics into neighboring markets. Fixed-dose tablets that combine metformin with DPP-4 inhibitors are positioned for short-term uptake because they simplify regimens for multi-morbid elderly patients. Ramadan-specific adherence research, such as the 2025 O-SEMA-FAST study, is informing culturally tailored prescribing patterns during fasting periods. Overall, competition is intensifying as biosimilar GLP-1s approach patent expiry in the late 2020s, at which point low-cost regional manufacturers plan to launch.

By Diabetes Type: Type 2 Shapes Long-Term Demand

Type 2 diabetes represented 91.55% of total cases in 2025, reinforcing its status as the cornerstone of commercial forecasting. The Middle East and Africa diabetes drugs market size for type 2 therapies is forecast to expand at an 8.21% CAGR thanks to earlier screening, wider CGM use, and employer-sponsored wellness schemes. Saudi registry data collected in 2024 reveal baseline HbA1c readings above 10%, validating physician calls for quicker intensification. In Egypt, domestic insulin glargine production is expected to lower unit prices, which could lift adherence among nearly 11 million diagnosed adults. 

Type 1 diabetes, though a smaller segment, remains clinically complex and cost intensive. The 2024 GCC endocrine consensus supports early adoption of hybrid closed-loop insulin pumps for children, but rollout depends on reimbursement approvals and skilled nursing staff. Teplizumab gained UAE compassionate-use clearance in late 2024, offering the first disease-modifying option for at-risk relatives. Market participants expect uptake to concentrate in tertiary centres before broadening once diagnostic antibody testing becomes routine.

By Distribution Channel: Omnichannel Dispensing Gains Ground

Hospital pharmacies held 48.10% of the Middle East and Africa diabetes drugs market share in 2025 as they handle complex titration cases and insurance pre-authorisations. Yet online outlets, expanding at an 11.05% CAGR, are the standout growth story. GCC legislation enacted in 2024 clarified cold-chain carriage, mandatory pharmacist counselling, and patient-data privacy requirements, energising venture-backed platforms to aggregate supply. Early adopters value doorstep delivery of sensors and pens, especially during extreme summer temperatures. 

Retail chains are pivoting to click-and-collect models and subscription-based refill packs, while wholesalers deploy predictive-analytics dashboards that feed electronic medical records. Ethiopia’s 2024 affordability survey highlights how flexible payment options at community pharmacies can cushion out-of-pocket shocks for families facing inflationary pressure. Combined, these shifts forge a hybrid ecosystem where patients initiate complex regimens in hospitals, refill through e-pharmacies, and tap retail outlets for over-the-counter test strips.

Geography Analysis

Saudi Arabia remains the largest national market with a 29.60% revenue contribution in 2025. Vision 2030’s localisation clauses compel global manufacturers to establish fill-and-finish plants, and the Saudi Food and Drug Authority’s 2024 fast-track framework cuts dossier review time to 60 days for breakthrough therapies. Demand is further buoyed by public-sector insurance that reimburses CGM devices for citizens. As localisation scales, the Middle East and Africa diabetes drugs market could see a reduction in import costs that benefits neighbouring Gulf states through intra-GCC trade.

The UAE delivers the highest forward CAGR at 8.79%. Dubai’s health-tourism hub status and Abu Dhabi’s 2024 collaboration with Sanofi on AI-driven screening position the federation as the region’s innovation sandbox. Federal Decree-Law No. 38 of 2025 unifies pharmacovigilance and post-marketing surveillance, an important enabler for first-in-region launches of dual-agonist injectables. 

South Africa anchors Sub-Saharan demand thanks to local insulin cartridge production that commenced in 2024 under a Novo Nordisk–Aspen venture. Egypt’s fast-growing population and newly built EVA Pharma insulin line broaden North-African self-sufficiency. Elsewhere, Nigeria and Kenya are piloting digital-wallet subsidy schemes that credit low-income patients each month, while conflict-affected areas grapple with counterfeit-medicine vigilance. Collectively, these developments reinforce geographical bifurcation: wealthier nations drive uptake of novel GLP-1s, and lower-income states concentrate on human insulin and generics.

Regulatory Landscape

Across the Middle East and Africa, market access for diabetes medicines is shaped by accelerated pathways in the GCC and fragmented approval systems in many African countries. In Saudi Arabia, the Saudi Food and Drug Authority (SFDA) requires eCTD-format dossiers for registration and renews marketing authorizations on a five-year cycle. SFDA also operates Verification and Abridged pathways for products already approved by stringent regulators such as the US FDA or EMA, which supports faster entry for novel antidiabetic drugs and biologics.

In the UAE, the Emirates Drug Establishment (EDE) under the Ministry of Health and Prevention (MoHAP) manages marketing authorization, with marketing authorization holders registered before product registration and certificates generally valid for five years. Federal Decree-Law No. 38 of 2025 formalized conditional approval pathways and mandatory pharmacovigilance, reinforcing post-marketing surveillance expectations for innovative therapies. In Africa, initiatives such as the AUDA-NEPAD-led African Medicines Regulatory Harmonization (AMRH) program are working to reduce duplication across national agencies, but companies still handle country-specific submission, pricing, and quality requirements, particularly for cold-chain biologics like insulin.

Value Chain Analysis

The regional value chain runs from imported APIs and excipients (commonly sourced from India and China) through formulation, fill-finish (especially for insulins and other injectables), packaging, and multi-tier distribution into hospital, retail, and online pharmacy channels. Localization efforts in key markets are reshaping upstream activities: Saudi Arabia and Egypt are using localization mandates and public procurement influence to pull manufacturing and technology transfer into the region, while South Africa has expanded insulin-related production capabilities via partnerships, supporting more resilient supply for neighboring markets.

Distribution and last-mile delivery remain a key operational constraint for temperature-sensitive products. Cold-chain gaps and temperature excursions in parts of Sub-Saharan Africa raise wastage risk and increase reliance on hospital-centered dispensing, while the GCC is expanding licensed e-pharmacy models under clarified online dispensing and cold-chain carriage rules. Public procurement and tendering remain critical for volume access in several African markets, but payment delays and registration bottlenecks can interrupt availability, increasing reliance on local distributors, track-and-trace initiatives, and public-private partnerships to stabilize supply for essential diabetes medicines.

Market Opportunities and Future Outlook

Localization and regional logistics buildouts are creating opportunities for manufacturers that can combine technology transfer with more dependable distribution. Saudi Arabia has active investment commitments tied to domestic supply of essential medicines, exemplified by STADA's February 2026 announcement to invest more than EUR 85 million in a Sudair City facility designed to produce treatments for type 2 diabetes at scale. In the UAE, Novo Nordisk announced in May 2026 a major regional distribution center serving markets across the Gulf and Africa, and in June 2026 the EDE and Novo Nordisk signed an MoU focused on manufacturing cooperation, advanced technology adoption, and supply-chain security, expanding the pathway for locally anchored supply of diabetes therapies.

Therapy upgrading and affordability-led substitution create parallel opportunities. Access to innovative incretin-based medicines is widening in insured GCC populations, while competitive entry points are emerging for high-volume markets through generics and biosimilars where regulators provide clear pathways and quality enforcement. A proof point is South Africa, where SAHPRA approval in July 2026 for Sun Pharma to manufacture and market a generic semaglutide injection creates a new competitive dynamic in GLP-1 therapy access. For Sub-Saharan Africa, opportunities center on strengthening cold-chain capability, reducing counterfeit exposure through verification and track-and-trace, and scaling public-private procurement models that keep human insulin and key oral agents consistently available through licensed channels.